Protection induced by early stage vaccination with pandemic influenza virus-like particles.
The 2009 worldwide influenza pandemic emphasized the need for new approaches to develop emergency vaccines. In this study, a virus-like particle vaccine comprised of hemagglutinin (HA) and M1 from the pandemic influenza virus A/California/04/09 were used and its ability to induce protective immunity during the early stage of vaccination was assessed in a mouse model. A single intramuscular vaccination with virus-like particles (VLPs) provided protection on days 4 and 7 post-vaccination against lethal virus challenge with only moderate body weight loss. VLP vaccination induced significantly higher IgG antibody responses and high hemagglutinin inhibition (HAI) titers on day 4 post-vaccination. A predominant IgG2a antibody response and viral neutralizing antibodies were induced on day 7. These immune responses were closely correlated with protection. Lung virus titers decreased significantly on day 7 compared to those on day 4 post-vaccination. The lung virus titer on day 4 post-vaccination also decreased significantly compared to that of the naïve control. These results demonstrate that VLP vaccination confers effective protection during the early stage after vaccination in a mouse model.
Department of Biomedical Engineering, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Gi-Ja
GJ
Lee
Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul, Republic of Korea. Electronic address: fsquan@khu.ac.kr.
Fu-Shi
FS
Quan
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D016207:Cytokines / Q000276:immunology; D005260:Female; D006385:Hemagglutination Inhibition Tests; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000276:immunology*; D008168:Lung / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000276:immunology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D016207:Cytokines; D007074:Immunoglobulin G; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; D058425:Vaccines, Virus-Like Particle; D014763:Viral Matrix Proteins
H1N1 influenza; Protection; Virus-like particle